Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The facility is expected to be completed in 2029, and will add 80 new jobs.
September 10, 2026
By: Patrick Lavery
Editor’s Take: Spray-dried dispersion technologies are increasingly important amid growing molecule complexity and related bioavailability challenges.
Lonza plans to construct a large-scale commercial spray-drying facility in Bend, Ore. The company says the investment reinforces the Bend site as a center of excellence for particle engineering and bioavailability enhancement.
Bioavailability is a major challenge in an environment of growing molecule complexity, heightening the need for spray-dried dispersion (SDD) technologies. The new site in Bend will have two state-of-the-art PSD-4 spray-drying units.
According to Lonza, that will make the company the United States’ leading CDMO provider of commercial-scale spray-drying PSD-4 capacity. The company says demand for SDD CDMO services has grown thanks to increasing complexities in pharmaceutical pipelines.
A “full range” of SDD capacity will support customers in both clinical and commercial settings, Lonza says. The integrated end-to-end offerings of the Bend site encourage development and manufacturing of small molecules, biologics, and mRNA.
“[This] reflects our conviction that the U.S. will remain a leading source of pharmaceutical innovation,” Lonza CEO Wolfgang Wienand said. “By significantly expanding our commercial-scale spray-drying capabilities, we strengthen a technology that can fundamentally improve delivery and bioavailability of medicines. With this, our world-class particle engineering team in Bend will be even better able to support our customers.”
Lonza says the facility is made possible through a “significant capital investment.” Exact terms of that are not public. Work should be completed in 2029, and will initially create more than 80 new jobs. Not only expanding Lonza’s U.S. manufacturing footprint, the facility will also enhance proximity to key customers and ease supply chains.
Additional proposed upgrades to the Bend site include supporting infrastructure for solvent handling and storage.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !